AgingNCT07566832
Velocity-Based Resistance Training Effects on Inflammation in Older Adults
A study testing Resistance exercise in people with Aging and Inflammatory Response, run by National Taipei University at 1 site in Taiwan.
Trial summary
This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Read more about this study
- Who is it for?
- Ages 60 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Aging, Inflammatory Response
- What is being tested?
- Resistance exercise
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- 20 Apr 2026to Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Aged 60-75 years or older
- No regular resistance training habit (defined as ≥2 sessions per week) in the past year
- No musculoskeletal injuries within the past six months
Who cannot join
- Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
- Regular use of anti-inflammatory medications (e.g., NSAIDs).
- Smoking or alcohol abuse
- Inability to safely perform the prescribed resistance exercise movements
- Unable to fully comprehend the study information and instructions.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan Normal University
Taipei, 116
Hung-Wen Liu, Ph.D., +88677496863, hwliu@ntnu.edu.tw
Kuan-Tsen Yeh, M.S., +886932815383, mickyyehyeh@gmail.com
About this study
Official title: Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults
This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.
- Conditions
- Aging, Inflammatory Response
- Being tested
- Resistance exercise
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance exerciseOther
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
| Study group | Role | What they receive |
|---|---|---|
| low training volume resistance exercise | Experimental | Participants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% from the first repetition. Rest intervals of 2-3 minutes will be provided between exercises. Receives: Other: Resistance exercise |
| medium training volume resistance exercise | Experimental | Participants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises. Receives: Other: Resistance exercise |
| high training volume resistance exercise | Experimental | Participants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises. Receives: Other: Resistance exercise |
| sedentary control | No intervention | Participants in control trial stayed sedentary during the period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in IL-6 concentration
Plasma IL-6 concentrations will be measured and reported in pg/mL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble IL-6 receptor concentration
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble gp130 concentration
Soluble gp130 concentrations will be measured and reported in ng/mL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-10 concentration
IL-10 concentrations will be measured and reported in pg/mL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-1RA concentration
IL-1RA concentrations will be measured and reported in pg/mL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in TNF-α concentration
TNF-α concentrations will be measured and reported in pg/mL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Secondary outcomes (19)
Borgs Ratings of Perceived Exertion (RPE)
Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).
Measured: 1-hour during each exercise intervention
Handgrip strength
Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Knee extension strength
Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
30-second chair-stand test
Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Single-leg balance test
Balance performance will be assessed as the duration of single-leg stance and reported in seconds.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Timed up and go test
Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in gp130 (CD130) protein expression in PBMCs
Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in STAT3 protein expression in PBMCs
Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in phosphorylated STAT3 protein expression in PBMCs
Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SOCS3 protein expression in PBMCs
Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in white blood cell count
Total white blood cell count will be measured and reported in cells/μL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in lymphocyte count
Lymphocyte count will be measured and reported in cells/μL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in neutrophil count
Neutrophil count will be measured and reported in cells/μL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in monocyte count
Monocyte count will be measured and reported in cells/μL.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage
Body fat percentage will be measured using a body composition analyzer and reported as a percentage.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lean body mass
Total lean body mass will be measured using a body composition analyzer and reported in kilograms.
Measured: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2026
- Study start20 Apr 2026
- Primary completionMar 2029 (estimated)
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taipei University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shun-Hsi Tsai, Ph.D., Principal investigator, National Taipei University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07566832
- Sponsor's protocol ID
- ECKIRB1140803
- Status last verified
- Apr 2026
- First submitted
- 15 Apr 2026
- Last updated
- 8 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults
- ClinicalTrials.gov ID
- NCT07566832
- Acronym / sponsor ID
- ECKIRB1140803
- Conditions
- Aging, Inflammatory Response
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- National Taipei UniversityUniversity, hospital or other
- Study start
- 20 Apr 2026 (actual)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Dec 2029 (estimated)
- First posted
- 5 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| low training volume resistance exercise | Experimental | Other: Resistance exerciseParticipants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% from the first repetition. Rest intervals of 2-3 minutes will be provided between exercises. |
| medium training volume resistance exercise | Experimental | Other: Resistance exerciseParticipants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises. |
| high training volume resistance exercise | Experimental | Other: Resistance exerciseParticipants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises. |
| sedentary control | No intervention | –Participants in control trial stayed sedentary during the period. |
Who may qualify
- Ages
- 60 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Aged 60-75 years or older
- No regular resistance training habit (defined as ≥2 sessions per week) in the past year
- No musculoskeletal injuries within the past six months
Key exclusion criteria (5 listed)
- Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
- Regular use of anti-inflammatory medications (e.g., NSAIDs).
- Smoking or alcohol abuse
- Inability to safely perform the prescribed resistance exercise movements
- Unable to fully comprehend the study information and instructions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance exerciseThe RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press. | Other | high training volume resistance exercise, low training volume resistance exercise, medium training volume resistance exercise |
Primary outcome
Changes in IL-6 concentration
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Plasma IL-6 concentrations will be measured and reported in pg/mL.
Changes in soluble IL-6 receptor concentration
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
Changes in soluble gp130 concentration
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble gp130 concentrations will be measured and reported in ng/mL.
Changes in IL-10 concentration
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-10 concentrations will be measured and reported in pg/mL.
Changes in IL-1RA concentration
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-1RA concentrations will be measured and reported in pg/mL.
Changes in TNF-α concentration
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
TNF-α concentrations will be measured and reported in pg/mL.
19 secondary outcomes
Borgs Ratings of Perceived Exertion (RPE)
Time frame: 1-hour during each exercise intervention
Handgrip strength
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Knee extension strength
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
30-second chair-stand test
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Single-leg balance test
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Timed up and go test
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in gp130 (CD130) protein expression in PBMCs
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in STAT3 protein expression in PBMCs
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in phosphorylated STAT3 protein expression in PBMCs
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SOCS3 protein expression in PBMCs
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in white blood cell count
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in lymphocyte count
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in neutrophil count
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in monocyte count
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lean body mass
Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2026.
- Individual participant dataSharing planned: No
Related trials for Aging
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Shun-Hsi Tsai, Ph.D. principal investigator
National Taipei University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance exercise in people with Aging and Inflammatory Response, run by National Taipei University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Shun-Hsi Tsai, Ph.D. (+88686741111 ext. 68523, shunhsi@mail.ntpu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in IL-6 concentration (time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2026.